Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

The introduction of high-efficacy therapies for relapsing–remitting multiple sclerosis has driven re-evaluation of treatment goals and benefit:risk considerations in treatment choice. In the alemtuzumab Phase II and III clinical trials, patients treated with alemtuzumab 12 mg versus subcutaneous int...

Descripción completa

Detalles Bibliográficos
Autores principales: Havrdova, Eva, Cohen, Jeffrey A, Horakova, Dana, Kovarova, Ivana, Meluzinova, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652900/
https://www.ncbi.nlm.nih.gov/pubmed/29081658
http://dx.doi.org/10.2147/TCRM.S143509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652900/
https://www.ncbi.nlm.nih.gov/pubmed/29081658
http://dx.doi.org/10.2147/TCRM.S143509

Ejemplares similares